{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:20:49Z","timestamp":1791822049460,"version":"4.3.4"},"reference-count":318,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T00:00:00Z","timestamp":1615507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:p>Antipsychotic medications are critical to child and adolescent psychiatry, from the stabilization of psychotic disorders like schizophrenia, bipolar disorder, and psychotic depression to behavioral treatment of autism spectrum disorder, tic disorders, and pediatric aggression. While effective, these medications carry serious risk of adverse events\u2014most commonly, weight gain and cardiometabolic abnormalities. Negative metabolic consequences affect up to 60% of patients and present a major obstacle to long-term treatment. Since antipsychotics are often chronically prescribed beginning in childhood, cardiometabolic risk accumulates. An increased susceptibility to antipsychotic-induced weight gain (AIWG) has been repeatedly documented in children, particularly rapid weight gain. Associated cardiometabolic abnormalities include central obesity, insulin resistance, dyslipidemia, and systemic inflammation. Lifestyle interventions and medications such as metformin have been proposed to reduce risk but remain limited in efficacy. Furthermore, antipsychotic medications touted to be weight-neutral in adults can cause substantial weight gain in children. A better understanding of the biological underpinnings of AIWG could inform targeted and potentially more fruitful treatments; however, little is known about the underlying mechanism. As yet, modest genetic studies have nominated a few risk genes that explain only a small percentage of the risk. Recent investigations have begun to explore novel potential mechanisms of AIWG, including a role for gut microbiota and microbial metabolites. This article reviews the problem of AIWG and AP metabolic side effects in pediatric populations, proposed mechanisms underlying this serious side effect, and strategies to mitigate adverse impact. We suggest future directions for research efforts that may advance the field and lead to improved clinical interventions.<\/jats:p>","DOI":"10.3389\/fpsyt.2021.623681","type":"journal-article","created":{"date-parts":[[2021,3,11]],"date-time":"2021-03-11T23:21:17Z","timestamp":1615504877000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":100,"title":["The Burden of Antipsychotic-Induced Weight Gain and Metabolic Syndrome in Children"],"prefix":"10.3389","volume":"12","author":[{"given":"Mark R.","family":"Libowitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika L.","family":"Nurmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,3,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"757","DOI":"10.2147\/TCRM.S117321","article-title":"Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review","volume":"13","author":"Solmi","year":"2017","journal-title":"Ther Clin Risk Manag"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e771","DOI":"10.1542\/peds.2011-2158","article-title":"Antipsychotics for children and young adults: a comparative effectiveness review","volume":"129","author":"Seida","year":"2012","journal-title":"Pediatrics"},{"key":"B3","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1093\/schbul\/sbu170","article-title":"Treatments of negative symptoms in schizophrenia: meta-analysis of 168 randomized placebo-controlled trials","volume":"41","author":"Fusar-Poli","year":"2015","journal-title":"Schizophr Bull"},{"key":"B4","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1002\/pds.2082","article-title":"Increasing off-label use of antipsychotic medications in the United States, 1995-2008","volume":"20","author":"Alexander","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"B5","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1097\/01.chi.0000157543.74509.c8","article-title":"Trends in the use of typical and atypical antipsychotics in children and adolescents","volume":"44","author":"Patel","year":"2005","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"B6","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.mayocp.2016.09.017","article-title":"Review of childhood obesity: from epidemiology, etiology, and comorbidities to clinical assessment and treatment","volume":"92","author":"Kumar","year":"2017","journal-title":"Mayo Clin Proc"},{"key":"B7","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/j.jaac.2013.02.008","article-title":"Practice parameter for the assessment and treatment of children and adolescents with schizophrenia","volume":"52","author":"McClellan","year":"2013","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"B8","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s00787-014-0631-y","article-title":"Recent international trends in psychotropic medication prescriptions for children and adolescents","volume":"24","author":"Steinhausen","year":"2015","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1007\/s00228-019-02711-3","article-title":"Prescription prevalence of psychotropic drugs in children and adolescents: an analysis of international data","volume":"75","author":"Piovani","year":"2019","journal-title":"Eur J Clin Pharmacol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1016\/j.euroneuro.2017.07.001","article-title":"International trends in antipsychotic use: a study in 16 countries, 2005-2014","volume":"27","author":"Halfdanarson","year":"2017","journal-title":"Eur Neuropsychopharmacol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1001\/archgenpsychiatry.2012.647","article-title":"National trends in the office-based treatment of children, adolescents, and adults with antipsychotics","volume":"69","author":"Olfson","year":"2012","journal-title":"Arch Gen Psychiatry"},{"key":"B12","doi-asserted-by":"publisher","first-page":"927","DOI":"10.2165\/00128072-200103120-00005","article-title":"Tolerability profile of atypical antipsychotics in children and adolescents","volume":"3","author":"Stigler","year":"2001","journal-title":"Paediatr Drugs"},{"key":"B13","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/S0278-5846(01)00264-0","article-title":"A retrospective chart review of risperidone use in treatment-resistant children and adolescents with psychiatric disorders","volume":"26","author":"Simeon","year":"2002","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"B14","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1097\/00004583-200302000-00008","article-title":"Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY)","volume":"42","author":"Pappadopulos","year":"2003","journal-title":"Part II J Am Acad Child Adolesc Psychiatry"},{"key":"B15","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1001\/archpedi.158.8.753","article-title":"New users of antipsychotic medications among children enrolled in TennCare","volume":"158","author":"Cooper","year":"2004","journal-title":"Arch Pediatr Adolesc Med"},{"key":"B16","first-page":"12","article-title":"Phenomenology and epidemiology of childhood psychiatric disorders that may necessitate treatment with atypical antipsychotics","volume":"65","author":"DelBello","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"B17","unstructured":"Treatment of comorbidity in conduct disorder with attention-deficit hyperactivity disorder (ADHD)27790\n            TurgayA\n          16222912Essent Psychopharmacol62005"},{"key":"B18","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1377\/hlthaff.22.5.39","article-title":"Trends and issues in child and adolescent mental health","volume":"22","author":"Glied","year":"2003","journal-title":"Health Aff."},{"key":"B19","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1176\/ps.2008.59.5.554","article-title":"Use of antipsychotic drugs among dutch youths between 1997 and 2005","volume":"59","author":"Kalverdijk","year":"2008","journal-title":"Psychiatr Serv"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1542\/peds.2007-2008","article-title":"Epidemiologic features of antipsychotic prescribing to children and adolescents in primary care in the United Kingdom","volume":"121","author":"Rani","year":"2008","journal-title":"Pediatrics"},{"key":"B21","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1093\/pch\/16.9.581","article-title":"Evidence-based recommendations for monitoring safety of second generation antipsychotics in children and youth","volume":"20","author":"Pringsheim","year":"2011","journal-title":"J Can Accad Child Adolesc Psychiatry"},{"key":"B22","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1176\/appi.ps.201200081","article-title":"Antipsychotic use by medicaid-insured youths: impact of eligibility and psychiatric diagnosis across a decade","volume":"64","author":"Zito","year":"2013","journal-title":"Psychiatr Serv"},{"key":"B23","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3238\/arztebl.2014.0025","article-title":"Antipsychotic prescription in children and adolescents: an analysis of data from a German statutory health insurance company from 2005 to 2012","volume":"111","author":"Bachmann","year":"2014","journal-title":"Dtsch Arztebl Int"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.2147\/NDT.S113099","article-title":"Antipsychotic-associated weight gain: management strategies and impact on treatment adherence","volume":"13","author":"Dayabandara","year":"2017","journal-title":"Neuropsychiatr Dis Treat"},{"key":"B25","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1177\/0004867417691851","article-title":"Average duration of treatment with antipsychotics among concession card holders in Australia","volume":"51","author":"Kjosavik","year":"2017","journal-title":"Aust N Z J Psychiatry"},{"key":"B26","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1089\/cap.2010.0145","article-title":"The pharmacoepidemiology of antipsychotic medications for Canadian children and adolescents: 2005-2009","volume":"21","author":"Pringsheim","year":"2011","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1001\/jamapediatrics.2018.0240","article-title":"Patterns of early mental health diagnosis and medication treatment in a medicaid-insured birth cohort","volume":"172","author":"Pennap","year":"2018","journal-title":"JAMA Pediatr"},{"key":"B28","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.jaac.2010.03.013","article-title":"Double-blind maintenance safety and effectiveness findings from the treatment of early-onset schizophrenia spectrum (TEOSS) study","volume":"49","author":"Findling","year":"2010","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"B29","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1097\/JCP.0b013e3182962480","article-title":"Twenty-four months of antipsychotic treatment in children and adolescents with first psychotic episode: discontinuation and tolerability","volume":"33","author":"Noguera","year":"2013","journal-title":"J Clin Psychopharmacol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.psychres.2019.05.005","article-title":"Reversibility of psychotropic medication induced weight gain among children and adolescents with bipolar disorders","volume":"276","author":"Upadhyay","year":"2019","journal-title":"Psychiatry Res"},{"key":"B31","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1177\/000992280404300504","article-title":"Discontinuation of risperidone and reversibility of weight gain in children with disruptive behavior disorders","volume":"43","author":"Lindsay","year":"2004","journal-title":"Clin Pediatr."},{"key":"B32","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1176\/appi.ajp.163.3.402","article-title":"A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders","volume":"163","author":"Reyes","year":"2006","journal-title":"Am J Psychiatry"},{"key":"B33","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1089\/cap.2013.0126","article-title":"Cardiometabolic outcomes in children and adolescents following discontinuation of long-term risperidone treatment","volume":"24","author":"Calarge","year":"2014","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1177\/0706743718779950","article-title":"Harms of antipsychotics in children and young adults: a systematic review update","volume":"63","author":"Pillay","year":"2018","journal-title":"Can J Psychiatry"},{"key":"B35","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1089\/cap.2011.0015","article-title":"Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents","volume":"21","author":"Maayan","year":"2011","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.3390\/cells8111336","article-title":"Second-generation antipsychotics and dysregulation of glucose metabolism: beyond weight gain","volume":"8","author":"Grajales","year":"2019","journal-title":"Cells"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/j.euroneuro.2019.10.006","article-title":"Incidence of adverse events in antipsychotic-naive children and adolescents treated with antipsychotic drugs: Results of a multicenter naturalistic study (ETAPE)","volume":"29","author":"Menard","year":"2019","journal-title":"Eur Neuropsychopharmacol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1007\/s13679-019-00357-x","article-title":"Metabolic syndrome in children and adolescents: diagnostic criteria, therapeutic options and perspectives","volume":"8","author":"Weihe","year":"2019","journal-title":"Curr Obes Rep"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.005632","article-title":"Childhood Age and associations between childhood metabolic syndrome and adult risk for metabolic syndrome, type 2 diabetes mellitus and carotid intima media thickness: the international childhood cardiovascular cohort consortium","volume":"6","author":"Koskinen","year":"2017","journal-title":"J Am Heart Assis"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1001\/jama.2009.1549","article-title":"Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents","volume":"302","author":"Correll","year":"2009","journal-title":"JAMA"},{"key":"B41","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1089\/cap.2010.0020","article-title":"Comparison of long-term (at least 24 weeks) weight gain and metabolic changes between adolescents and adults treated with olanzapine","volume":"22","author":"Kryzhanovskaya","year":"2012","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1345\/aph.1L015","article-title":"Antipsychotics and diabetes: an age-related association","volume":"42","author":"Hammerman","year":"2008","journal-title":"Ann Pharmacother"},{"key":"B43","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.schres.2010.12.007","article-title":"Schizophrenia patients at higher risk of diabetes, hypertension and hyperlipidemia: a population-based study","volume":"126","author":"Liao","year":"2011","journal-title":"Schizophr Res"},{"key":"B44","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.jaac.2014.04.023","article-title":"Risk of diabetes in children and adolescents exposed to antipsychotics: a nationwide 12-year case-control study","volume":"53","author":"Nielsen","year":"2014","journal-title":"J Am Acad Child Adolesc Psychiatry."},{"key":"B45","doi-asserted-by":"publisher","first-page":"e150285","DOI":"10.1001\/jamapediatrics.2015.0285","article-title":"Risk for incident diabetes mellitus following initiation of second-generation antipsychotics among Medicaid-enrolled youths","volume":"169","author":"Rubin","year":"2015","journal-title":"JAMA Pediatr"},{"key":"B46","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1001\/archpedi.162.10.929","article-title":"Metabolic and cardiovascular adverse events associated with antipsychotic treatment in children and adolescents","volume":"162","author":"McIntyre","year":"2008","journal-title":"Arch Pediatr Adolesc Med"},{"key":"B47","doi-asserted-by":"publisher","first-page":"11m01185","DOI":"10.4088\/PCC.11m01185","article-title":"The risk of developing type 2 diabetes mellitus associated with psychotropic drug use in children and adolescents: a retrospective cohort analysis","volume":"14","author":"Jerrell","year":"2012","journal-title":"Prim Care Companion CNS Disord"},{"key":"B48","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1002\/pds.1016","article-title":"Atypical antipsychotic drugs and diabetes mellitus in a large outpatient population: a retrospective cohort study","volume":"14","author":"Ostbye","year":"2005","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1542\/peds.2011-0855","article-title":"Antipsychotic medication use among children and risk of diabetes mellitus","volume":"128","author":"Andrade","year":"2011","journal-title":"Pediatrics"},{"key":"B50","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1196\/annals.1429.009","article-title":"Adolescent obesity and puberty: the \u201cperfect storm\u201d","volume":"1135","author":"Jasik","year":"2008","journal-title":"Ann N Y Acad Sic"},{"key":"B51","doi-asserted-by":"publisher","first-page":"149","DOI":"10.4081\/pmc.2017.149","article-title":"Second-generation antipsychotic and diabetes mellitus in children and adolescents","volume":"39","author":"Ripoli","year":"2017","journal-title":"Pediatr Med Chir"},{"key":"B52","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1592\/phco.22.11.841.33629","article-title":"Olanzapine-associated diabetes mellitus","volume":"22","author":"Koller","year":"2002","journal-title":"Pharmacotherapy"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1176\/appi.ajp.2008.08050756","article-title":"Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study","volume":"165","author":"Sikich","year":"2008","journal-title":"Am J Psychiatry"},{"key":"B54","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1002\/j.2051-5545.2008.tb00154.x","article-title":"Side effects of atypical antipsychotics: a brief overview","volume":"7","author":"Ucok","year":"2008","journal-title":"World Psychiatry"},{"key":"B55","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1089\/cap.2008.007","article-title":"Weight gain and metabolic abnormalities during extended risperidone treatment in children and adolescents","volume":"19","author":"Calarge","year":"2009","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1016\/j.jpeds.2012.05.051","article-title":"Rate of weight gain and cardiometabolic abnormalities in children and adolescents","volume":"161","author":"Calarge","year":"2012","journal-title":"J Pediatr"},{"key":"B57","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1517\/14740338.2015.974549","article-title":"Weight gain and antipsychotics: a drug safety review","volume":"14","author":"Musil","year":"2015","journal-title":"Expert Opin Drug Saf"},{"key":"B58","doi-asserted-by":"publisher","first-page":"232","DOI":"10.3109\/10398562.2010.539609","article-title":"Weight gain and metabolic syndrome among young patients on antipsychotic medication: what do we know and where do we go?","volume":"19","author":"Eapen","year":"2011","journal-title":"Australas Psychiatry"},{"key":"B59","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1056\/NEJMoa013171","article-title":"Risperidone in children with autism and serious behavioral problems","volume":"347","author":"McCracken","year":"2002","journal-title":"N Engl J Med"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1001\/jamapsychiatry.2013.2053","article-title":"Antipsychotics and the risk of type 2 diabetes mellitus in children and youth","volume":"70","author":"Bobo","year":"2013","journal-title":"JAMA Psychiatry"},{"key":"B61","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.jaac.2017.04.004","article-title":"Concomitant use of atypical antipsychotics with other psychotropic medication classes and the risk of type 2 diabetes mellitus","volume":"56","author":"Burcu","year":"2017","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"B62","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s00787-013-0399-5","article-title":"Weight gain and increase of body mass index among children and adolescents treated with antipsychotics: a critical review","volume":"22","author":"Martinez-Ortega","year":"2013","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"B63","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1097\/00004583-200203000-00014","article-title":"Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study","volume":"41","author":"Ratzoni","year":"2002","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"B64","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1097\/01.jcp.0000130558.86125.5b","article-title":"A comparison of risperidone-induced weight gain across the age span","volume":"24","author":"Safer","year":"2004","journal-title":"J Clin Psychopharmacol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s12916-019-1346-1","article-title":"The effects of antipsychotic medications on microbiome and weight gain in children and adolescents","volume":"17","author":"Bretler","year":"2019","journal-title":"BMC Med"},{"key":"B66","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.eurpsy.2010.09.011","article-title":"Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: a systematic review of randomized, placebo controlled trials and guidelines for clinical practice","volume":"26","author":"De Hert","year":"2011","journal-title":"Eur Psychiatry"},{"key":"B67","doi-asserted-by":"publisher","first-page":"547","DOI":"10.2165\/00023210-200822070-00002","article-title":"Antipsychotic-induced weight gain in chronic and first-episode psychotic disorders: a systematic critical reappraisal","volume":"22","author":"Alvarez-Jimenez","year":"2008","journal-title":"CNS Drugs"},{"key":"B68","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1001\/jamapsychiatry.2014.1314","article-title":"Cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders: baseline results from the RAISE-ETP study","volume":"71","author":"Correll","year":"2014","journal-title":"JAMA Psychiatry"},{"key":"B69","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/j.jaac.2019.01.015","article-title":"Cardiometabolic adverse effects and its predictors in children and adolescents with first-episode psychosis during treatment with quetiapine-extended release versus aripiprazole: 12-week results from the tolerance and effect of antipsychotics in children and adolescents with psychosis (TEA) trial","volume":"58","author":"Jensen","year":"2019","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"B70","doi-asserted-by":"publisher","first-page":"596","DOI":"10.2337\/diacare.27.2.596","article-title":"Consensus development conference on antipsychotic drugs and obesity and diabetes","volume":"27","year":"2004","journal-title":"Diabetes Care"},{"key":"B71","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.4088\/JCP.v69n0717","article-title":"Metabolic and hormonal side effects in children and adolescents treated with second-generation antipsychotics","volume":"69","author":"Fraguas","year":"2008","journal-title":"J Clin Psychiatry"},{"key":"B72","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1001\/archpediatrics.2010.48","article-title":"Metabolic screening in children receiving antipsychotic drug treatment","volume":"164","author":"Morrato","year":"2010","journal-title":"Arch Pediatr Adolesc Med"},{"key":"B73","first-page":"234","article-title":"Management recommendations for metabolic complications associated with second generation antipsychotic use in children and youth","volume":"20","author":"Ho","year":"2011","journal-title":"J Can Accad Child Adolesc Psychiatry"},{"key":"B74","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1089\/cap.2013.0094","article-title":"Atypical antipsychotic use among Medicaid-insured children and adolescents: duration, safety, and monitoring implications","volume":"24","author":"Burcu","year":"2014","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1097\/JCP.0000000000000760","article-title":"Feasibility and relevance of antipsychotic safety monitoring in children with tourette syndrome: a prospective longitudinal study","volume":"37","author":"Pringsheim","year":"2017","journal-title":"J Clin Psychopharmacol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1089\/cap.2015.0247","article-title":"Pediatric Antipsychotic use and outcomes monitoring","volume":"27","author":"Santosh","year":"2017","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"e425","DOI":"10.1097\/MJT.0000000000000853","article-title":"Metabolic monitoring of child and adolescent patients on atypical antipsychotics by psychiatrists and primary care providers","volume":"27","author":"Wakefield","year":"2020","journal-title":"Am J Ther"},{"key":"B78","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.euroneuro.2018.03.008","article-title":"Efficacy, acceptability, and tolerability of antipsychotics in children and adolescents with schizophrenia: a network meta-analysis","volume":"28","author":"Krause","year":"2018","journal-title":"Eur Neuropsychopharmacol"},{"key":"B79","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1089\/cap.2018.0092","article-title":"Weight-change trajectories of pediatric outpatients treated with risperidone or aripiprazole in a naturalistic setting","volume":"29","author":"Pozzi","year":"2019","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1089\/cap.2018.0111","article-title":"No differences in weight gain between risperidone and aripiprazole in children and adolescents after 12 months","volume":"29","author":"Schoemakers","year":"2019","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"B81","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.4088\/JCP.08r04392","article-title":"Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review","volume":"70","author":"Simon","year":"2009","journal-title":"J Clin Psychiatry"},{"key":"B82","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1176\/appi.ajp.2020.177901","article-title":"The American psychiatric association practice guideline for the treatment of patients with schizophrenia","volume":"177","author":"Keepers","year":"2020","journal-title":"Am J Psychiatry"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1007\/s00787-020-01614-4","article-title":"Risk factors and pattern of weight gain in youths using antipsychotic drugs","volume":"1","author":"van der Esch","year":"2020","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"B84","first-page":"12","article-title":"Atypical antipsychotic augmentation of mood stabilizer therapy in bipolar disorder","volume":"66","author":"Bowden","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"B85","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1089\/cap.2017.0147","article-title":"Predictors and moderators of antipsychotic-related weight gain in the treatment of early-onset schizophrenia spectrum disorders study","volume":"28","author":"Taylor","year":"2018","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"B86","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1177\/0269881116645254","article-title":"BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment","volume":"30","author":"Cooper","year":"2016","journal-title":"J Psychopharmacol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"e274","DOI":"10.1038\/tp.2013.26","article-title":"Moderation of antipsychotic-induced weight gain by energy balance gene variants in the RUPP autism network risperidone studies","volume":"3","author":"Nurmi","year":"2013","journal-title":"Transl Psychiatry"},{"key":"B88","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1586\/ern.10.85","article-title":"Management of antipsychotic-related weight gain","volume":"10","author":"Maayan","year":"2010","journal-title":"Expert Rev Neurother"},{"key":"B89","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.4088\/JCP.v66n1118","article-title":"Long-term weight gain in patients treated with open-label olanzapine in combination with fluoxetine for major depressive disorder","volume":"66","author":"Andersen","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"B90","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.jpsychires.2008.11.001","article-title":"Antipsychotic-induced body weight gain: predictors and a systematic categorization of the long-term weight course","volume":"43","author":"Gebhardt","year":"2009","journal-title":"J Psychiatr Res"},{"key":"B91","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.2217\/pgs.09.102","article-title":"Sex-specific differences in side effects of psychotropic drugs: genes or gender?","volume":"10","author":"Haack","year":"2009","journal-title":"Pharmacogenomics"},{"key":"B92","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S2215-0366(19)30416-X","article-title":"Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis","volume":"7","author":"Pillinger","year":"2020","journal-title":"Lancet Psychiatry"},{"key":"B93","doi-asserted-by":"publisher","first-page":"864","DOI":"10.4088\/JCP.v65n0620","article-title":"Atypical antipsychotics and weight gain in Chinese patients: a comparison of olanzapine and risperidone","volume":"65","author":"Lee","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"B94","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.jpsychires.2008.01.004","article-title":"Ethnic heterogeneity in glucoregulatory function during treatment with atypical antipsychotics in patients with schizophrenia","volume":"42","author":"Ader","year":"2008","journal-title":"J Psychiatr Res"},{"key":"B95","doi-asserted-by":"publisher","first-page":"e157","DOI":"10.1542\/peds.2007-0212","article-title":"Psychotropic medication patterns among youth in foster care","volume":"121","author":"Zito","year":"2008","journal-title":"Pediatrics"},{"key":"B96","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1001\/archpedi.159.4.362","article-title":"Prevalence of atypical antipsychotic drug use among commercially insured youths in the United States","volume":"159","author":"Curtis","year":"2005","journal-title":"Arch Pediatr Adolesc Med"},{"key":"B97","doi-asserted-by":"publisher","first-page":"w770","DOI":"10.1377\/hlthaff.28.5.w770","article-title":"Broadened use of atypical antipsychotics: safety, effectiveness, and policy challenges","volume":"28","author":"Crystal","year":"2009","journal-title":"Health Aff."},{"key":"B98","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0024-3205(00)00911-5","article-title":"Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds","volume":"68","author":"Richelson","year":"2000","journal-title":"Life Sci"},{"key":"B99","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/sj.npp.1300027","article-title":"H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs","volume":"28","author":"Kroeze","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"B100","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1124\/jpet.110.167346","article-title":"Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity","volume":"334","author":"Ishibashi","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"key":"B101","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.2165\/11596300-000000000-00000","article-title":"Atypical antipsychotic-induced weight gain: insights into mechanisms of action","volume":"25","author":"Roerig","year":"2011","journal-title":"CNS Drugs"},{"key":"B102","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1038\/mp.2011.109","article-title":"Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications","volume":"17","author":"Lett","year":"2012","journal-title":"Mol Psychiatry"},{"key":"B103","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/sj.mp.4002066","article-title":"Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles","volume":"13","author":"Nasrallah","year":"2008","journal-title":"Mol Psychiatry"},{"key":"B104","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1093\/bioinformatics\/btq061","article-title":"iPHACE: integrative navigation in pharmacological space","volume":"26","author":"Garcia-Serna","year":"2010","journal-title":"Bioinformatics"},{"key":"B105","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.pharmthera.2009.10.010","article-title":"Metabolic side effects of antipsychotic drug treatment\u2013pharmacological mechanisms","volume":"125","author":"Reynolds","year":"2010","journal-title":"Pharmacol Ther"},{"key":"B106","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/nature11691","article-title":"Automated design of ligands to polypharmacological profiles","volume":"492","author":"Besnard","year":"2012","journal-title":"Nature"},{"key":"B107","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1124\/jpet.114.213793","article-title":"Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator","volume":"350","author":"Maeda","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"key":"B108","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.euroneuro.2014.11.010","article-title":"The pharmacodynamic properties of lurasidone and their role in its antidepressant efficacy in bipolar disorder","volume":"25","author":"Fountoulakis","year":"2015","journal-title":"Eur Neuropsychopharmacol"},{"key":"B109","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.pharmthera.2015.01.005","article-title":"Clozapine and GABA transmission in schizophrenia disease models: establishing principles to guide treatments","volume":"150","author":"O'Connor","year":"2015","journal-title":"Pharmacol Ther"},{"key":"B110","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.2174\/1570159X15666170630163616","article-title":"Antipsychotic drugs: from receptor-binding profiles to metabolic side effects","volume":"16","author":"Siafis","year":"2018","journal-title":"Curr Neuropharmacol"},{"key":"B111","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1016\/S0924-9338(10)71701-6","article-title":"From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics","volume":"25","author":"Correll","year":"2010","journal-title":"Eur Psychiatry"},{"key":"B112","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.molmed.2010.10.010","article-title":"Antipsychotic drugs and obesity","volume":"17","author":"Correll","year":"2011","journal-title":"Trends Mol Med"},{"key":"B113","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1176\/appi.ajp.157.4.514","article-title":"Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia","volume":"157","author":"Kapur","year":"2000","journal-title":"Am J Psychiatry"},{"key":"B114","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.neures.2007.08.001","article-title":"Effect of chronic treatment with clozapine and haloperidol on 5-HT(2A and 2C) receptor mRNA expression in the rat brain","volume":"59","author":"Huang","year":"2007","journal-title":"Neurosci Res"},{"key":"B115","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1192\/bjp.173.3.236","article-title":"5-HT2A receptor blockade in patients with schizophrenia treated with risperidone or clozapine. A SPET study using the novel 5-HT2A ligand 123I-5-I-R-91150","volume":"173","author":"Travis","year":"1998","journal-title":"Br J Psychiatry"},{"key":"B116","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S0006-3223(98)00186-3","article-title":"Hypothalamic serotonin in control of eating behavior, meal size, and body weight","volume":"44","author":"Leibowitz","year":"1998","journal-title":"Biol Psychiatry"},{"key":"B117","first-page":"226","article-title":"Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors","volume":"295","author":"Herrick-Davis","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"B118","first-page":"83","article-title":"Inverse agonist actions of typical and atypical antipsychotic drugs at the human 5-hydroxytryptamine(2C) receptor","volume":"299","author":"Rauser","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"B119","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1038\/sj.npp.1300203","article-title":"Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology","volume":"28","author":"Shapiro","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"B120","volume-title":"Reduce the Olanzapine-Induced Body Weight Gain With Histamine H1 Receptor Agonist Betahistine in Rats","author":"Lian","year":"2010"},{"key":"B121","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1177\/0269881115626349","article-title":"Betahistine decreases olanzapine-induced weight gain and somnolence in humans","volume":"30","author":"Barak","year":"2016","journal-title":"J Psychopharmacol."},{"key":"B122","doi-asserted-by":"publisher","first-page":"3456","DOI":"10.1073\/pnas.0611417104","article-title":"From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase","volume":"104","author":"Kim","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"B123","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.tem.2014.07.004","article-title":"Molecular pathophysiology of metabolic effects of antipsychotic medications","volume":"25","author":"Ballon","year":"2014","journal-title":"Trends Endocrinol Metab"},{"key":"B124","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.jpsychires.2009.11.007","article-title":"Relationship between body mass index and insulin resistance in patients treated with second generation antipsychotic agents","volume":"44","author":"Kim","year":"2010","journal-title":"J Psychiatr Res"},{"key":"B125","doi-asserted-by":"publisher","first-page":"3385","DOI":"10.2174\/1568026616666160608084834","article-title":"Dopamine Targeting Drugs for the Treatment of Schizophrenia: Past, Present and Future","volume":"16","author":"Li","year":"2016","journal-title":"Curr Top Med Chem"},{"key":"B126","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/S0278-5846(01)00266-4","article-title":"Studies on modulation of feeding behavior by atypical antipsychotics in female mice","volume":"26","author":"Kaur","year":"2002","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"B127","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/S0140-6736(00)03643-6","article-title":"Brain dopamine and obesity","volume":"357","author":"Wang","year":"2001","journal-title":"Lancet"},{"key":"B128","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1300\/J069v23n03_04","article-title":"Similarity between obesity and drug addiction as assessed by neurofunctional imaging: a concept review","volume":"23","author":"Wang","year":"2004","journal-title":"J Addict Dis"},{"key":"B129","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1097\/01.jcp.0000203196.65710.2b","article-title":"Risperidone-related weight gain: genetic and nongenetic predictors","volume":"26","author":"Lane","year":"2006","journal-title":"J Clin Psychopharmacol"},{"key":"B130","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1002\/hup.903","article-title":"An investigation of the alpha1A-adrenergic receptor gene and antipsychotic-induced side-effects","volume":"23","author":"Saiz","year":"2008","journal-title":"Hum Psychopharmacol"},{"key":"B131","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.schres.2011.06.004","article-title":"Atypical antipsychotics and effects of muscarinic, serotonergic, dopaminergic and histaminergic receptor binding on insulin secretion in vivo: an animal model","volume":"131","author":"Hahn","year":"2011","journal-title":"Schizophr Res"},{"key":"B132","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s00787-016-0866-x","article-title":"The effects of antipsychotics on weight gain, weight-related hormones and homocysteine in children and adolescents: a 1-year follow-up study","volume":"26","author":"Baeza","year":"2017","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"B133","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1177\/153537020122601102","article-title":"Peripheral signals conveying metabolic information to the brain: short-term and long-term regulation of food intake and energy homeostasis","volume":"226","author":"Havel","year":"2001","journal-title":"Exp Biol Med."},{"key":"B134","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s12944-020-01203-z","article-title":"Leptin and psychiatric illnesses: does leptin play a role in antipsychotic-induced weight gain?","volume":"19","author":"Endomba","year":"2020","journal-title":"Lipids Health Dis"},{"key":"B135","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1097\/MED.0000000000000184","article-title":"Leptin applications in 2015: what have we learned about leptin and obesity?","volume":"22","author":"Farr","year":"2015","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"B136","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1210\/me.2015-1232","article-title":"Minireview: CNS mechanisms of leptin action","volume":"30","author":"Flak","year":"2016","journal-title":"Mol Endocrinol"},{"key":"B137","doi-asserted-by":"publisher","first-page":"191","DOI":"10.2147\/DMSO.S182406","article-title":"Leptin resistance: underlying mechanisms and diagnosis","volume":"12","author":"Gruzdeva","year":"2019","journal-title":"Diabetes Metab Syndr Obes"},{"key":"B138","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.metabol.2014.08.004","article-title":"Physiology of leptin: energy homeostasis, neuroendocrine function and metabolism","volume":"64","author":"Park","year":"2015","journal-title":"Metab Clin Exp"},{"key":"B139","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.cmet.2013.08.015","article-title":"Leptin, GABA, and glucose control","volume":"18","author":"Kahn","year":"2013","journal-title":"Cell Metab"},{"key":"B140","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.psyneuen.2015.09.026","article-title":"Are leptin levels increased among people with schizophrenia versus controls? A systematic review and comparative meta-analysis","volume":"63","author":"Stubbs","year":"2016","journal-title":"Psychoneuroendocrinology"},{"key":"B141","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1097\/00004714-200208000-00015","article-title":"Pronounced early increase in circulating leptin predicts a lower weight gain during clozapine treatment","volume":"22","author":"Monteleone","year":"2002","journal-title":"J Clin Psychopharmacol"},{"key":"B142","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1016\/S0140-6736(02)08913-4","article-title":"Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism","volume":"359","author":"Reynolds","year":"2002","journal-title":"Lancet"},{"key":"B143","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1007\/s10517-008-0294-0","article-title":"Contribution of leptin to the formation of neuroleptic obesity in patients with schizophrenia during antipsychotic therapy","volume":"146","author":"Gorobets","year":"2008","journal-title":"Bull Exp Biol Med"},{"key":"B144","doi-asserted-by":"publisher","first-page":"999","DOI":"10.2217\/pgs.11.45","article-title":"Pharmacogenetics of leptin in antipsychotic-associated weight gain and obesity-related complications","volume":"12","author":"Lee","year":"2011","journal-title":"Pharmacogenomics"},{"key":"B145","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.pnpbp.2012.03.001","article-title":"Association study of polymorphisms in leptin and leptin receptor genes with antipsychotic-induced body weight gain","volume":"38","author":"Brandl","year":"2012","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"B146","first-page":"145","article-title":"Leptin\u22122548g\/a gene polymorphism in association with antipsychotic-induced weight gain: a meta-analysis study","volume":"26","author":"Shen","year":"2014","journal-title":"Psychiatr Danub"},{"key":"B147","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/sj.npp.1300563","article-title":"Plasma leptin and adiposity during antipsychotic treatment of schizophrenia","volume":"30","author":"Haupt","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"B148","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1097\/01213011-200504000-00002","article-title":"Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis","volume":"15","author":"Templeman","year":"2005","journal-title":"Pharmacogenet Genomics"},{"key":"B149","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1590\/S1807-59322010000900012","article-title":"The impact of antipsychotic drugs on food intake and body weight and on leptin levels in blood and hypothalamic ob-r leptin receptor expression in wistar rats","volume":"65","author":"von Wilmsdorff","year":"2010","journal-title":"Clinics."},{"key":"B150","doi-asserted-by":"publisher","first-page":"572848","DOI":"10.1155\/2012\/572848","article-title":"The role of leptin in antipsychotic-induced weight gain: genetic and non-genetic factors","volume":"2012","author":"Panariello","year":"2012","journal-title":"J Obes"},{"key":"B151","first-page":"26","article-title":"Antipsychotic-induced changes in blood levels of leptin in schizophrenia: a meta-analysis","volume":"60","author":"Potvin","year":"2015","journal-title":"Can J Psychiatry."},{"key":"B152","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.neubiorev.2019.05.018","article-title":"Appetite regulating hormones in first-episode psychosis: a systematic review and meta-analysis","volume":"102","author":"Misiak","year":"2019","journal-title":"Neurosci Biobehav Rev"},{"key":"B153","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.cca.2012.12.007","article-title":"Role of leptin and adiponectin in insulin resistance","volume":"417","author":"Yadav","year":"2013","journal-title":"Clin Chim Acta"},{"key":"B154","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1038\/nm0796-800","article-title":"Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity","volume":"2","author":"Shimomura","year":"1996","journal-title":"Nat Med"},{"key":"B155","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1210\/jc.83.3.847","article-title":"Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid","volume":"83","author":"Fried","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"B156","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.physbeh.2011.05.033","article-title":"Atypical antipsychotics and the neural regulation of food intake and peripheral metabolism","volume":"104","author":"Teff","year":"2011","journal-title":"Physiol Behav"},{"key":"B157","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1590\/1516-4446-2012-1052","article-title":"Recent evidence and potential mechanisms underlying weight gain and insulin resistance due to atypical antipsychotics","volume":"35","author":"Volpato","year":"2013","journal-title":"Braz J Psychiatry"},{"key":"B158","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2337\/diabetes.50.2.385","article-title":"Targeted disruption of histamine H1-receptor attenuates regulatory effects of leptin on feeding, adiposity, and UCP family in mice","volume":"50","author":"Masaki","year":"2001","journal-title":"Diabetes"},{"key":"B159","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.physbeh.2011.04.018","article-title":"Apolipoprotein E reduces food intake via PI3K\/Akt signaling pathway in the hypothalamus","volume":"105","author":"Shen","year":"2011","journal-title":"Physiol Behav"},{"key":"B160","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/S2213-8587(20)30113-3","article-title":"Central nervous pathways of insulin action in the control of metabolism and food intake","volume":"8","author":"Kullmann","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B161","doi-asserted-by":"publisher","first-page":"12103","DOI":"10.1073\/pnas.0604404103","article-title":"The cerebrocortical response to hyperinsulinemia is reduced in overweight humans: a magnetoencephalographic study","volume":"103","author":"Tschritter","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"B162","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/nrg862","article-title":"Genetic approaches to studying energy balance: perception and integration","volume":"3","author":"Barsh","year":"2002","journal-title":"Nat Rev Genet"},{"key":"B163","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1159\/000341406","article-title":"Intranasal insulin modulates intrinsic reward and prefrontal circuitry of the human brain in lean women","volume":"97","author":"Kullmann","year":"2013","journal-title":"Neuroendocrinology"},{"key":"B164","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1002\/hbm.22304","article-title":"Intranasal insulin increases regional cerebral blood flow in the insular cortex in men independently of cortisol manipulation","volume":"35","author":"Schilling","year":"2014","journal-title":"Hum Brain Mapp"},{"key":"B165","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1111\/dom.13279","article-title":"Safety of intranasal human insulin: a review","volume":"20","author":"Schmid","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"B166","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1007\/s12035-013-8404-z","article-title":"Brain insulin dysregulation: implication for neurological and neuropsychiatric disorders","volume":"47","author":"Ghasemi","year":"2013","journal-title":"Mol Neurobiol"},{"key":"B167","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.2174\/1381612033454766","article-title":"The insulin-sensitizing role of the fat derived hormone adiponectin","volume":"9","author":"Heilbronn","year":"2003","journal-title":"Curr Pharm Des"},{"key":"B168","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1210\/jcem.86.5.7463","article-title":"Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia","volume":"86","author":"Weyer","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"B169","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1210\/er.2005-0005","article-title":"Adiponectin and adiponectin receptors","volume":"26","author":"Kadowaki","year":"2005","journal-title":"Endocr Rev"},{"key":"B170","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.psyneuen.2015.03.012","article-title":"Plasma adiponectin levels in schizophrenia and role of second-generation antipsychotics: a meta-analysis","volume":"56","author":"Bartoli","year":"2015","journal-title":"Psychoneuroendocrinology"},{"key":"B171","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1093\/schbul\/sbm141","article-title":"Leptin and ghrelin levels in patients with schizophrenia during different antipsychotics treatment: a review","volume":"34","author":"Sentissi","year":"2008","journal-title":"Schizophr Bull"},{"key":"B172","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.schres.2007.11.026","article-title":"Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin","volume":"100","author":"Jin","year":"2008","journal-title":"Schizophr Res"},{"key":"B173","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.schres.2018.12.043","article-title":"Do reductions in ghrelin contribute towards antipsychotic-induced weight gain?","volume":"210","author":"Firth","year":"2019","journal-title":"Schizophr Res"},{"key":"B174","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.schres.2018.11.036","article-title":"Meta-analysis of ghrelin alterations in schizophrenia: effects of olanzapine","volume":"206","author":"Goetz","year":"2019","journal-title":"Schizophr Res"},{"key":"B175","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1097\/YIC.0000000000000135","article-title":"The role of melatonin and melatonin agonists in counteracting antipsychotic-induced metabolic side effects: a systematic review","volume":"31","author":"Wang","year":"2016","journal-title":"Int Clin Psychopharmacol"},{"key":"B176","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1038\/sj.npp.1301093","article-title":"Olanzapine-induced weight gain and increased visceral adiposity is blocked by melatonin replacement therapy in rats","volume":"32","author":"Raskind","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"B177","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.physbeh.2013.04.006","article-title":"Melatonin reduces body weight gain and increases nocturnal activity in male wistar rats","volume":"118","author":"Terron","year":"2013","journal-title":"Physiol Behav"},{"key":"B178","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1111\/j.1365-2710.2009.01084.x","article-title":"Body weight gain induced by atypical antipsychotics: an extension of the monozygotic twin and sib pair study","volume":"35","author":"Gebhardt","year":"2010","journal-title":"J Clin Pharm Ther"},{"key":"B179","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1097\/JCP.0b013e3180a76dc0","article-title":"The association between HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia","volume":"27","author":"Mulder","year":"2007","journal-title":"J Clin Psychopharmacol"},{"key":"B180","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.pnpbp.2006.12.021","article-title":"\u2212759 C\/T polymorphism of 5-HT2C receptor gene and early phase weight gain associated with antipsychotic drug treatment","volume":"31","author":"Ryu","year":"2007","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"B181","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.psychres.2007.06.006","article-title":"The influence of 5-HT(2C) and MDR1 genetic polymorphisms on antipsychotic-induced weight gain in female schizophrenic patients","volume":"160","author":"Kuzman","year":"2008","journal-title":"Psychiatry Res"},{"key":"B182","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.2217\/pgs.10.123","article-title":"Polymorphisms of the HTR2C gene and antipsychotic-induced weight gain: an update and meta-analysis","volume":"11","author":"Sicard","year":"2010","journal-title":"Pharmacogenomics"},{"key":"B183","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/tpj.2010.7","article-title":"Association study of MDR1 and 5-HT2C genetic polymorphisms and antipsychotic-induced metabolic disturbances in female patients with schizophrenia","volume":"11","author":"Kuzman","year":"2011","journal-title":"Pharmacogenomics J"},{"key":"B184","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1097\/FPC.0b013e3283397d06","article-title":"Dopamine receptor D2 gene is associated with weight gain in schizophrenic patients under long-term atypical antipsychotic treatment","volume":"20","author":"Hong","year":"2010","journal-title":"Pharmacogenet Genomics"},{"key":"B185","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1097\/FPC.0b013e32833ca24b","article-title":"DRD2 promoter region variation predicts antipsychotic-induced weight gain in first episode schizophrenia","volume":"20","author":"Lencz","year":"2010","journal-title":"Pharmacogenet Genomics"},{"key":"B186","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/tpj.2010.65","article-title":"Systematic analysis of dopamine receptor genes. (DRD1-DRD5) in antipsychotic-induced weight gain","volume":"12","author":"Muller","year":"2012","journal-title":"Pharmacogenomics J"},{"key":"B187","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.psychres.2014.05.039","article-title":"Pharmacogenetics of adverse events in schizophrenia treatment: comparison study of ziprasidone, olanzapine and perazine","volume":"219","author":"Tybura","year":"2014","journal-title":"Psychiatry Res"},{"key":"B188","doi-asserted-by":"publisher","first-page":"28","DOI":"10.4103\/jpp.JPP_197_16","article-title":"Risperidone-induced adverse drug reactions and role of DRD2. (-141 C Ins\/Del) and 5HTR2C. (-759 C>T) genetic polymorphisms in patients with schizophrenia","volume":"8","author":"Alladi","year":"2017","journal-title":"J Pharmacol Pharmacother"},{"key":"B189","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1007\/s00702-005-0291-7","article-title":"Polymorphism of the adrenergic receptor alpha 2a\u22121291C>G genetic variation and clozapine-induced weight gain","volume":"112","author":"Wang","year":"2005","journal-title":"J Neural Transm."},{"key":"B190","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1002\/ajmg.b.30311","article-title":"Weight gain associated with the alpha2a-adrenergic receptor\u22121,291 C\/G polymorphism and olanzapine treatment","author":"Park","year":"2006","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"B191","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.2217\/pgs.09.43","article-title":"Association of the alpha 2A adrenergic receptor\u22121291C\/G polymorphism and antipsychotic-induced weight gain in European-Americans","volume":"10","author":"Sickert","year":"2009","journal-title":"Pharmacogenomics"},{"key":"B192","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1097\/JCP.0b013e3181fbfac4","article-title":"Association between the 1291-C\/G polymorphism in the adrenergic alpha-2a receptor and the metabolic syndrome","volume":"30","author":"Risselada","year":"2010","journal-title":"J Clin Psychopharmacol"},{"key":"B193","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1002\/hup.1219","article-title":"Genetic interactions in the adrenergic system genes: analysis of antipsychotic-induced weight gain","volume":"26","author":"De Luca","year":"2011","journal-title":"Hum Psychopharmacol"},{"key":"B194","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1097\/JCP.0b013e3181e742c5","article-title":"Endocannabinoid Pro129Thr FAAH functional polymorphism but not 1359G\/A CNR1 polymorphism is associated with antipsychotic-induced weight gain","volume":"30","author":"Monteleone","year":"2010","journal-title":"J Clin Psychopharmacol"},{"key":"B195","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1038\/npp.2009.235","article-title":"A common polymorphism in the cannabinoid receptor 1. (CNR1) gene is associated with antipsychotic-induced weight gain in Schizophrenia","volume":"35","author":"Tiwari","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"B196","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1002\/hup.1210","article-title":"Cannabinoid type 1 receptor gene polymorphisms are not associated with olanzapine-induced weight gain","volume":"26","author":"Park","year":"2011","journal-title":"Hum Psychopharmacol"},{"key":"B197","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1097\/JCP.0b013e318283925e","article-title":"CNR1 gene and risk of the metabolic syndrome in patients with schizophrenia","volume":"33","author":"Yu","year":"2013","journal-title":"J Clin Psychopharmacol"},{"key":"B198","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/tpj.2011.66","article-title":"Genetic association study between antipsychotic-induced weight gain and the melanocortin-4 receptor gene","volume":"13","author":"Chowdhury","year":"2013","journal-title":"Pharmacogenomics J"},{"key":"B199","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1017\/S1461145713000849","article-title":"MC4R rs489693: a clinical risk factor for second generation antipsychotic-related weight gain?","volume":"16","author":"Czerwensky","year":"2013","journal-title":"Int J Neuropsychopharmacol"},{"key":"B200","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s11427-018-9489-x","article-title":"Testing the role of genetic variation of the MC4R gene in Chinese population in antipsychotic-induced metabolic disturbance","volume":"62","author":"Zhang","year":"2019","journal-title":"Sci China Life Sci"},{"key":"B201","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1097\/JCP.0b013e31827772db","article-title":"Association of the common MC4R rs17782313 polymorphism with antipsychotic-related weight gain","volume":"33","author":"Czerwensky","year":"2013","journal-title":"J Clin Psychopharmacol"},{"key":"B202","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.pnpbp.2007.08.002","article-title":"Possible association between the\u22122548A\/G polymorphism of the leptin gene and olanzapine-induced weight gain","volume":"32","author":"Kang","year":"2008","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"B203","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1192\/bjp.bp.107.041723","article-title":"Influence of 5-HT2C receptor and leptin gene polymorphisms, smoking and drug treatment on metabolic disturbances in patients with schizophrenia","volume":"192","author":"Yevtushenko","year":"2008","journal-title":"Br J Psychiatry"},{"key":"B204","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1097\/YPG.0b013e32833b6378","article-title":"Association between LEP and LEPR gene polymorphisms and dyslipidemia in patients using atypical antipsychotic medication","volume":"20","author":"Gregoor","year":"2010","journal-title":"Psychiatr Genet"},{"key":"B205","doi-asserted-by":"publisher","first-page":"919","DOI":"10.2217\/pgs.11.40","article-title":"Polymorphisms of the LEP, LEPR and HTR2C gene: obesity and BMI change in patients using antipsychotic medication in a naturalistic setting","volume":"12","author":"Gregoor","year":"2011","journal-title":"Pharmacogenomics"},{"key":"B206","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/sj.mp.4002133","article-title":"Association between the insulin-induced gene 2 (INSIG2) and weight gain in a German sample of antipsychotic-treated schizophrenic patients: perturbation of SREBP-controlled lipogenesis in drug-related metabolic adverse effects?","volume":"14","author":"Le Hellard","year":"2009","journal-title":"Mol Psychiatry"},{"key":"B207","doi-asserted-by":"publisher","first-page":"773","DOI":"10.2217\/pgs.10.50","article-title":"Association of HTR2C, but not LEP or INSIG2, genes with antipsychotic-induced weight gain in a German sample","volume":"11","author":"Opgen-Rhein","year":"2010","journal-title":"Pharmacogenomics"},{"key":"B208","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1002\/hup.1111","article-title":"Association study of polymorphisms in insulin induced gene 2 (INSIG2) with antipsychotic-induced weight gain in European and African-American schizophrenia patients","volume":"25","author":"Tiwari","year":"2010","journal-title":"Hum Psychopharmacol"},{"key":"B209","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/tpj.2010.74","article-title":"Gene-gene interactions of the INSIG1 and INSIG2 in metabolic syndrome in schizophrenic patients treated with atypical antipsychotics","volume":"12","author":"Liou","year":"2012","journal-title":"Pharmacogenomics J"},{"key":"B210","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1038\/sj.npp.1301619","article-title":"BDNF levels and genotype are associated with antipsychotic-induced weight gain in patients with chronic schizophrenia","volume":"33","author":"Zhang","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"B211","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s12017-011-8159-5","article-title":"Association study of brain-derived neurotrophic factor gene polymorphisms and body weight change in schizophrenic patients under long-term atypical antipsychotic treatment","volume":"13","author":"Tsai","year":"2011","journal-title":"Neuromol Med"},{"key":"B212","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.pnpbp.2012.05.014","article-title":"The role of brain-derived neurotrophic factor (BDNF) gene variants in antipsychotic response and antipsychotic-induced weight gain","volume":"39","author":"Zai","year":"2012","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"B213","doi-asserted-by":"publisher","first-page":"e72652","DOI":"10.1371\/journal.pone.0072652","article-title":"Association study of Val66Met polymorphism in brain-derived neurotrophic factor gene with clozapine-induced metabolic syndrome: preliminary results","volume":"8","author":"Zhang","year":"2013","journal-title":"PLoS ONE"},{"key":"B214","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3109\/15622975.2014.984631","article-title":"The role of genetic variation across IL-1beta, IL-2, IL-6, and BDNF in antipsychotic-induced weight gain","volume":"16","author":"Fonseka","year":"2015","journal-title":"World J Biol Psychiatry"},{"key":"B215","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1097\/YIC.0000000000000142","article-title":"Association of the BDNF Val66Met polymorphism with BMI in chronic schizophrenic patients and healthy controls","volume":"31","author":"Fang","year":"2016","journal-title":"Int Clin Psychopharmacol"},{"key":"B216","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.schres.2019.09.015","article-title":"Relationship of SNAP25 variants with schizophrenia and antipsychotic-induced weight change in large-scale schizophrenia patients","volume":"215","author":"Guan","year":"2020","journal-title":"Schizophr Res"},{"key":"B217","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.3389\/fphar.2019.01669","article-title":"Progress in genetic polymorphisms related to lipid disturbances induced by atypical antipsychotic drugs","volume":"10","author":"Li","year":"2019","journal-title":"Front Pharmacol"},{"key":"B218","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/mp.2008.77","article-title":"Bias in genetic association studies and impact factor","volume":"14","author":"Munafo","year":"2009","journal-title":"Mol Psychiatry"},{"key":"B219","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1038\/ejhg.2010.26","article-title":"Replication of past candidate loci for common diseases and phenotypes in 100 genome-wide association studies","volume":"18","author":"Siontis","year":"2010","journal-title":"Eur J Hum Genet"},{"key":"B220","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1176\/appi.ajp.2018.18070881","article-title":"No support for historical candidate gene or candidate gene-by-interaction hypotheses for major depression across multiple large samples","volume":"176","author":"Border","year":"2019","journal-title":"Am J Psychiatry"},{"key":"B221","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00406-016-0765-7","article-title":"Candidate gene associations studies in psychiatry: time to move forward","volume":"267","author":"Arango","year":"2017","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"B222","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1001\/archgenpsychiatry.2012.191","article-title":"Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain","volume":"69","author":"Malhotra","year":"2012","journal-title":"Arch Gen Psychiatry"},{"key":"B223","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1038\/nn1073","article-title":"Brain-derived neurotrophic factor regulates energy balance downstream of melanocortin-4 receptor","volume":"6","author":"Xu","year":"2003","journal-title":"Nat Neurosci"},{"key":"B224","doi-asserted-by":"publisher","first-page":"14630","DOI":"10.1523\/JNEUROSCI.5412-09.2010","article-title":"A serotonin and melanocortin circuit mediates D-fenfluramine anorexia","volume":"30","author":"Xu","year":"2010","journal-title":"J Neurosci"},{"key":"B225","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N Engl J Med"},{"key":"B226","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/tpj.2015.59","article-title":"Genome-wide association study on antipsychotic-induced weight gain in the CATIE sample","volume":"16","author":"Brandl","year":"2016","journal-title":"Pharmacogenomics J"},{"key":"B227","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1017\/neu.2019.41","article-title":"Molecular pathway analysis associates alterations in obesity-related genes and antipsychotic-induced weight gain","volume":"32","author":"Corfitsen","year":"2020","journal-title":"Acta Neuropsychiatr"},{"key":"B228","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1093\/schbul\/sbv179","article-title":"Genome-wide association study suggested the PTPRD polymorphisms were associated with weight gain effects of atypical antipsychotic medications","volume":"42","author":"Yu","year":"2016","journal-title":"Schizophr Bull"},{"key":"B229","doi-asserted-by":"publisher","first-page":"2775","DOI":"10.1093\/emboj\/19.12.2775","article-title":"Impaired learning with enhanced hippocampal long-term potentiation in PTPdelta-deficient mice","volume":"19","author":"Uetani","year":"2000","journal-title":"EMBO J"},{"key":"B230","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s00702-018-1921-1","article-title":"Genetic validation study of protein tyrosine phosphatase receptor type D (PTPRD) gene variants and risk for antipsychotic-induced weight gain","volume":"126","author":"Maciukiewicz","year":"2019","journal-title":"J Neural Transm."},{"key":"B231","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.schres.2019.07.022","article-title":"Genome-wide association study on antipsychotic-induced weight gain in Europeans and African-Americans","volume":"212","author":"Maciukiewicz","year":"2019","journal-title":"Schizophr Res"},{"key":"B232","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1007\/s00125-013-2880-6","article-title":"Systematic evaluation of validated type 2 diabetes and glycaemic trait loci for association with insulin clearance","volume":"56","author":"Goodarzi","year":"2013","journal-title":"Diabetologia"},{"key":"B233","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1142\/9789813207813_0024","article-title":"Genome-wide interaction with selected type 2 diabetes loci reveals novel loci for type 2 diabetes in African Americans","volume":"22","author":"Keaton","year":"2017","journal-title":"Pac Symp Biocomput"},{"key":"B234","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.diabres.2010.10.016","article-title":"Association of the cell death-inducing DNA fragmentation factor alpha-like effector A (CIDEA) gene V115F (G\/T) polymorphism with phenotypes of metabolic syndrome in a Chinese population","volume":"91","author":"Zhang","year":"2011","journal-title":"Diabetes Res Clin Pract"},{"key":"B235","doi-asserted-by":"publisher","first-page":"5691","DOI":"10.1007\/s11033-013-2671-7","article-title":"The genetic contribution of CIDEA polymorphisms, haplotypes and loci interaction to obesity in a Han Chinese population","volume":"40","author":"Wu","year":"2013","journal-title":"Mol Biol Rep"},{"key":"B236","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1177\/0269881120907972","article-title":"A new genetic locus for antipsychotic-induced weight gain: a genome-wide study of first-episode psychosis patients using amisulpride (from the OPTiMiSE cohort)","volume":"34","author":"Ter Hark","year":"2020","journal-title":"J Psychopharmacol."},{"key":"B237","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1093\/schbul\/sbv019","article-title":"The optimization of treatment and management of schizophrenia in Europe (OPTiMiSE) trial: rationale for its methodology and a review of the effectiveness of switching antipsychotics","volume":"41","author":"Leucht","year":"2015","journal-title":"Schizophr Bull"},{"key":"B238","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1111\/j.1399-5448.2010.00747.x","article-title":"The growth hormone receptor (GHR) exon 3 polymorphism and its correlation with metabolic profiles in obese Chinese children","volume":"12","author":"Gao","year":"2011","journal-title":"Pediatr Diabetes."},{"key":"B239","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.gene.2013.10.035","article-title":"Genetic variants in selenoprotein P plasma 1 gene (SEPP1) are associated with fasting insulin and first phase insulin response in hispanics","volume":"534","author":"Hellwege","year":"2014","journal-title":"Gene"},{"key":"B240","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.orcp.2016.07.004","article-title":"Selenoprotein P is elevated in individuals with obesity, but is not independently associated with insulin resistance","volume":"11","author":"Chen","year":"2017","journal-title":"Obes Res Clin Pract"},{"key":"B241","doi-asserted-by":"publisher","first-page":"e2945","DOI":"10.1002\/jgm.2945","article-title":"Association of expression of selenoprotein P in mRNA and protein levels with metabolic syndrome in subjects with cardiovascular disease: results of the Selenegene study","volume":"19","author":"Gharipour","year":"2017","journal-title":"J Gene Med"},{"key":"B242","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1080\/09513590.2018.1460659","article-title":"The relationship between gestational diabetes mellitus and selenoprotein-P plasma 1 (SEPP1) gene polymorphisms","volume":"34","author":"Akbaba","year":"2018","journal-title":"Gynecol Endocrinol"},{"key":"B243","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s12020-018-1794-y","article-title":"Expression of the growth hormone receptor isoforms and its correlation with the metabolic profile in morbidly obese subjects","volume":"63","author":"Espinosa","year":"2019","journal-title":"Endocrine"},{"key":"B244","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1159\/000185525","article-title":"Transcriptional regulation of HMG-CoA synthase and HMG-CoA reductase genes by human ACBP","volume":"22","author":"Vock","year":"2008","journal-title":"Cell Physiol Biochem"},{"key":"B245","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1016\/j.ebiom.2015.10.018","article-title":"Risperidone-induced weight gain is mediated through shifts in the gut microbiome and suppression of energy expenditure","volume":"2","author":"Bahr","year":"2015","journal-title":"EBioMedicine"},{"key":"B246","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/s41398-018-0116-8","article-title":"Prebiotic attenuation of olanzapine-induced weight gain in rats: analysis of central and peripheral biomarkers and gut microbiota","volume":"8","author":"Kao","year":"2018","journal-title":"Transl Psychiatry"},{"key":"B247","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/978-1-4939-9554-7_31","article-title":"The probiotic mixture VSL#3 reverses olanzapine-induced metabolic dysfunction in mice","volume":"2011","author":"Dhaliwal","year":"2019","journal-title":"Methods Mol Biol"},{"key":"B248","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1007\/s00213-018-5102-6","article-title":"Second-generation antipsychotics and metabolism alterations: a systematic review of the role of the gut microbiome","volume":"236","author":"Skonieczna-Zydecka","year":"2019","journal-title":"Psychopharmacology."},{"key":"B249","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s00213-011-2555-2","article-title":"Gender-dependent consequences of chronic olanzapine in the rat: effects on body weight, inflammatory, metabolic and microbiota parameters","volume":"221","author":"Davey","year":"2012","journal-title":"Psychopharmacology."},{"key":"B250","doi-asserted-by":"publisher","first-page":"e309","DOI":"10.1038\/tp.2013.83","article-title":"Antipsychotics and the gut microbiome: olanzapine-induced metabolic dysfunction is attenuated by antibiotic administration in the rat","volume":"3","author":"Davey","year":"2013","journal-title":"Transl Psychiatry"},{"key":"B251","doi-asserted-by":"publisher","first-page":"e115225","DOI":"10.1371\/journal.pone.0115225","article-title":"The antipsychotic olanzapine interacts with the gut microbiome to cause weight gain in mouse","volume":"9","author":"Morgan","year":"2014","journal-title":"PLoS ONE"},{"key":"B252","doi-asserted-by":"publisher","first-page":"e652","DOI":"10.1038\/tp.2015.135","article-title":"Use of the second-generation antipsychotic, risperidone, and secondary weight gain are associated with an altered gut microbiota in children","volume":"5","author":"Bahr","year":"2015","journal-title":"Transl Psychiatry"},{"key":"B253","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1089\/chi.2018.0040","article-title":"Childhood obesity and firmicutes\/bacteroidetes ratio in the gut microbiota: a systematic review","volume":"14","author":"Indiani","year":"2018","journal-title":"Child Obes"},{"key":"B254","doi-asserted-by":"publisher","first-page":"4095789","DOI":"10.1155\/2018\/4095789","article-title":"The gut microbiome profile in obesity: a systematic review","volume":"2018","author":"Castaner","year":"2018","journal-title":"Int J Endocrinol"},{"key":"B255","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/nature07540","article-title":"A core gut microbiome in obese and lean twins","volume":"457","author":"Turnbaugh","year":"2009","journal-title":"Nature"},{"key":"B256","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1038\/oby.2011.111","article-title":"Responses of gut microbiota to diet composition and weight loss in lean and obese mice","volume":"20","author":"Ravussin","year":"2012","journal-title":"Obesity."},{"key":"B257","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.chom.2008.02.015","article-title":"Diet-induced obesity is linked to marked but reversible alterations in the mouse distal gut microbiome","volume":"3","author":"Turnbaugh","year":"2008","journal-title":"Cell Host Microbe"},{"key":"B258","doi-asserted-by":"publisher","first-page":"1241214","DOI":"10.1126\/science.1241214","article-title":"Gut microbiota from twins discordant for obesity modulate metabolism in mice","volume":"341","author":"Ridaura","year":"2013","journal-title":"Science"},{"key":"B259","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1089\/chi.2015.0194","article-title":"Relative abundance in bacterial and fungal gut microbes in obese children: a case control study","volume":"13","author":"Borgo","year":"2017","journal-title":"Child Obes"},{"key":"B260","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/nrmicro2540","article-title":"Unravelling the effects of the environment and host genotype on the gut microbiome","volume":"9","author":"Spor","year":"2011","journal-title":"Nat Rev Microbiol"},{"key":"B261","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nature11053","article-title":"Human gut microbiome viewed across age and geography","volume":"486","author":"Yatsunenko","year":"2012","journal-title":"Nature"},{"key":"B262","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.cell.2014.03.011","article-title":"Role of the microbiota in immunity and inflammation","volume":"157","author":"Belkaid","year":"2014","journal-title":"Cell"},{"key":"B263","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/phar.1890","article-title":"Interaction between atypical antipsychotics and the gut microbiome in a bipolar disease cohort","volume":"37","author":"Flowers","year":"2017","journal-title":"Pharmacotherapy"},{"key":"B264","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/wps.20714","article-title":"Metformin add-on vs. antipsychotic switch vs continued antipsychotic treatment plus healthy lifestyle education in overweight or obese youth with severe mental illness: results from the IMPACT trial","volume":"19","author":"Correll","year":"2020","journal-title":"World Psychiatry"},{"key":"B265","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1089\/cap.2016.0010","article-title":"A 52-week study of olanzapine with a randomized behavioral weight counseling intervention in adolescents with schizophrenia or bipolar I disorder","volume":"26","author":"Detke","year":"2016","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"B266","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1089\/cap.2018.0120","article-title":"Adiposity, hepatic triglyceride, and carotid intima media thickness during behavioral weight loss treatment in antipsychotic-treated youth: a randomized pilot study","volume":"29","author":"Nicol","year":"2019","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"B267","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3390\/medsci8030034","article-title":"Integrative management of metabolic syndrome in youth prescribed second-generation antipsychotics","volume":"8","author":"Rice","year":"2020","journal-title":"Med Sci."},{"key":"B268","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1002\/wps.20614","article-title":"The impact of pharmacological and non-pharmacological interventions to improve physical health outcomes in people with schizophrenia: a meta-review of meta-analyses of randomized controlled trials","volume":"18","author":"Vancampfort","year":"2019","journal-title":"World Psychiatry"},{"key":"B269","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1038\/nature05414","article-title":"An obesity-associated gut microbiome with increased capacity for energy harvest","volume":"444","author":"Turnbaugh","year":"2006","journal-title":"Nature"},{"key":"B270","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1111\/j.1462-2920.2012.02845.x","article-title":"Microbiota from the distal guts of lean and obese adolescents exhibit partial functional redundancy besides clear differences in community structure","volume":"15","author":"Ferrer","year":"2013","journal-title":"Environ Microbiol"},{"key":"B271","doi-asserted-by":"publisher","first-page":"790","DOI":"10.3945\/ajcn.116.140947","article-title":"Prebiotic supplementation improves appetite control in children with overweight and obesity: a randomized controlled trial","volume":"105","author":"Hume","year":"2017","journal-title":"Am J Clin Nutr"},{"key":"B272","doi-asserted-by":"publisher","DOI":"10.4088\/PCC.13m01579","article-title":"Effect of probiotic supplementation on schizophrenia symptoms and association with gastrointestinal functioning: a randomized, placebo-controlled trial","volume":"15","author":"Dickerson","year":"2014","journal-title":"Prim Care Companion CNS Disord"},{"key":"B273","doi-asserted-by":"publisher","first-page":"47","DOI":"10.4137\/BMI.S22007","article-title":"Immunomodulatory effects of probiotic supplementation in schizophrenia patients: a randomized, placebo-controlled trial","volume":"10","author":"Tomasik","year":"2015","journal-title":"Biomark Insights"},{"key":"B274","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.psyneuen.2017.12.004","article-title":"Obesity exacerbates the acute metabolic side effects of olanzapine","volume":"88","author":"Townsend","year":"2018","journal-title":"Psychoneuroendocrinology"},{"key":"B275","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaac.2018.07.749","volume-title":"Do Microbiome-Bile Acid Interactions Explain Antipsychotic-Induced Weight Gain","author":"Nurmi","year":"2018"},{"key":"B276","volume-title":"Altered Bile Acid Signaling Correlates With Antipsychotic-Induced Weight Gain in Children","author":"Nurmi","year":"2019"},{"key":"B277","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1038\/s41591-018-0222-4","article-title":"Gut microbiota and intestinal FXR mediate the clinical benefits of metformin","volume":"24","author":"Sun","year":"2018","journal-title":"Nat Med"},{"key":"B278","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1080\/14740338.2019.1674809","article-title":"Strategies to counter antipsychotic-associated weight gain in patients with schizophrenia","volume":"18","author":"Marteene","year":"2019","journal-title":"Expert Opin Drug Saf"},{"key":"B279","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1177\/0269881107077815","article-title":"Statins are effective in treating dyslipidemia among psychiatric patients using second-generation antipsychotic agents","volume":"22","author":"Ojala","year":"2008","journal-title":"J Psychopharmacol."},{"key":"B280","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1097\/MED.0000000000000095","article-title":"Effects of metformin on weight loss: potential mechanisms","volume":"21","author":"Malin","year":"2014","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"B281","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1093\/schbul\/sbu030","article-title":"Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-analysis","volume":"40","author":"Mizuno","year":"2014","journal-title":"Schizophr Bull"},{"key":"B282","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1001\/jamapsychiatry.2016.1232","article-title":"Metformin for treatment of overweight induced by atypical antipsychotic medication in young people with autism spectrum disorder: a randomized clinical trial","volume":"73","author":"Anagnostou","year":"2016","journal-title":"JAMA Psychiatry"},{"key":"B283","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1089\/cap.2008.094","article-title":"Metformin for weight control in pediatric patients on atypical antipsychotic medication","volume":"19","author":"Shin","year":"2009","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"B284","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1176\/appi.ajp.159.4.655","article-title":"Metformin for weight loss in pediatric patients taking psychotropic drugs","volume":"159","author":"Morrison","year":"2002","journal-title":"Am J Psychiatry"},{"key":"B285","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/j.jaac.2017.07.790","article-title":"A randomized, placebo-controlled trial of metformin for the treatment of overweight induced by antipsychotic medication in young people with autism spectrum disorder: open-label extension","volume":"56","author":"Handen","year":"2017","journal-title":"J Am Acad Child Adolesc Psychiatry."},{"key":"B286","first-page":"1130","article-title":"A randomized, double-blind, placebo-controlled trial of metformin treatment for weight gain associated with initiation of risperidone in children and adolescents","volume":"29","author":"Arman","year":"2008","journal-title":"Saudi Med J"},{"key":"B287","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1038\/npp.2010.21","article-title":"Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis","volume":"35","author":"Maayan","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"B288","first-page":"120","article-title":"Minimizing weight gain for patients taking antipsychotic medications: the potential role for early use of metformin","volume":"29","author":"Hendrick","year":"2017","journal-title":"Ann Clin Psychiatry"},{"key":"B289","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/1741-7015-10-92","article-title":"Glucagon-like peptide-1 analogs against antipsychotic-induced weight gain: potential physiological benefits","volume":"10","author":"Ebdrup","year":"2012","journal-title":"BMC Med"},{"key":"B290","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.schres.2014.05.003","article-title":"Clozapine directly increases insulin and glucagon secretion from islets: implications for impairment of glucose tolerance","volume":"157","author":"Smith","year":"2014","journal-title":"Schizophr Res"},{"key":"B291","doi-asserted-by":"publisher","first-page":"3232","DOI":"10.2337\/db13-0430","article-title":"Antipsychotic-induced insulin resistance and postprandial hormonal dysregulation independent of weight gain or psychiatric disease","volume":"62","author":"Teff","year":"2013","journal-title":"Diabetes"},{"key":"B292","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1111\/dom.13522","article-title":"Glucagon-like peptide-1 receptor agonists for antipsychotic-associated cardio-metabolic risk factors: a systematic review and individual participant data meta-analysis","volume":"21","author":"Siskind","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"B293","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1159\/000439323","article-title":"Glucagon-like peptide-1 receptor agonist treatment for pediatric obesity","volume":"30","author":"Kelly","year":"2016","journal-title":"Endocr Dev"},{"key":"B294","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s00213-012-2935-2","article-title":"Reducing antipsychotic-induced weight gain in schizophrenia: a double-blind placebo-controlled study of reboxetine-betahistine combination","volume":"226","author":"Poyurovsky","year":"2013","journal-title":"Psychopharmacology."},{"key":"B295","doi-asserted-by":"publisher","first-page":"620","DOI":"10.3389\/fpsyt.2018.00620","article-title":"Effect of betahistine and metformin on antipsychotic-induced weight gain: an analysis of two clinical trials","volume":"9","author":"Kang","year":"2018","journal-title":"Front Psychiatry"},{"key":"B296","doi-asserted-by":"publisher","first-page":"3545","DOI":"10.1007\/s00213-018-5079-1","article-title":"Betahistine effects on weight-related measures in patients treated with antipsychotic medications: a double-blind placebo-controlled study","volume":"235","author":"Smith","year":"2018","journal-title":"Psychopharmacology."},{"key":"B297","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1177\/0269881112449396","article-title":"Reducing olanzapine-induced weight gain side effect by using betahistine: a study in the rat model","volume":"26","author":"Deng","year":"2012","journal-title":"J Psychopharmacol."},{"key":"B298","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.pnpbp.2013.08.005","article-title":"Effects of olanzapine and betahistine co-treatment on serotonin transporter, 5-HT2A and dopamine D2 receptor binding density","volume":"47","author":"Lian","year":"2013","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"B299","doi-asserted-by":"publisher","first-page":"e104160","DOI":"10.1371\/journal.pone.0104160","article-title":"Preventing olanzapine-induced weight gain using betahistine: a study in a rat model with chronic olanzapine treatment","volume":"9","author":"Lian","year":"2014","journal-title":"PLoS ONE"},{"key":"B300","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.psyneuen.2014.06.010","article-title":"Betahistine ameliorates olanzapine-induced weight gain through modulation of histaminergic, NPY and AMPK pathways","volume":"48","author":"Lian","year":"2014","journal-title":"Psychoneuroendocrinology"},{"key":"B301","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.pnpbp.2014.08.006","article-title":"Chronic betahistine co-treatment reverses olanzapine's effects on dopamine D(2) but not 5-HT2A\/2C bindings in rat brains","volume":"56","author":"Lian","year":"2015","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"B302","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.phrs.2016.02.011","article-title":"Ameliorating antipsychotic-induced weight gain by betahistine: mechanisms and clinical implications","volume":"106","author":"Lian","year":"2016","journal-title":"Pharmacol Res"},{"key":"B303","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1080\/13651501.2018.1449864","article-title":"Topiramate mitigates weight gain in antipsychotic-treated patients with schizophrenia: meta-analysis of randomised controlled trials","volume":"23","author":"Goh","year":"2019","journal-title":"Int J Psychiatry Clin Pract"},{"key":"B304","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1177\/0091217415621266","article-title":"Topiramate, zonisamide and weight loss in children and adolescents prescribed psychiatric medications: a medical record review","volume":"51","author":"Shapiro","year":"2016","journal-title":"Int J Psychiatry Med"},{"key":"B305","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/jpi.12137","article-title":"Melatonin, energy metabolism, and obesity: a review","volume":"56","author":"Cipolla-Neto","year":"2014","journal-title":"J Pineal Res"},{"key":"B306","first-page":"734","article-title":"Melatonin decreases olanzapine induced metabolic side-effects in adolescents with bipolar disorder: a randomized double-blind placebo-controlled trial","volume":"52","author":"Mostafavi","year":"2014","journal-title":"Acta Med Iran"},{"key":"B307","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1089\/cap.2016.0046","article-title":"Melatonin for reducing weight gain following administration of atypical antipsychotic olanzapine for adolescents with bipolar disorder: a randomized, double-blind, placebo-controlled trial","volume":"27","author":"Mostafavi","year":"2017","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"B308","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1046\/j.1365-2826.2003.00989.x","article-title":"Role of melatonin in the regulation of human circadian rhythms and sleep","volume":"15","author":"Cajochen","year":"2003","journal-title":"J Neuroendocrinol"},{"key":"B309","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1111\/obr.12444","article-title":"Sleep quality and obesity in young subjects: a meta-analysis","volume":"17","author":"Fatima","year":"2016","journal-title":"Obes Rev"},{"key":"B310","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1097\/JCP.0000000000000596","article-title":"Subjective versus objective weight gain during acute treatment with second-generation antipsychotics in schizophrenia and bipolar disorder","volume":"36","author":"Gao","year":"2016","journal-title":"J Clin Psychopharmacol"},{"key":"B311","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1007\/s11606-016-3712-4","article-title":"Diabetes and cardiovascular care among people with severe mental illness: a literature review","volume":"31","author":"Mangurian","year":"2016","journal-title":"J Gen Intern Med"},{"key":"B312","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1093\/schbul\/sbr148","article-title":"Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders\u2013a systematic review and meta-analysis","volume":"39","author":"Mitchell","year":"2013","journal-title":"Schizophr Bull"},{"key":"B313","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s00213-002-1344-3","article-title":"Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study","volume":"166","author":"Casey","year":"2003","journal-title":"Psychopharmacology."},{"key":"B314","doi-asserted-by":"publisher","first-page":"580","DOI":"10.4088\/JCP.v64n0514","article-title":"Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia","volume":"64","author":"Weiden","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"B315","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1080\/14656566.2019.1685496","article-title":"An up-to-date evaluation of lorcaserin hydrochloride for the treatment of obesity","volume":"21","author":"Tchang","year":"2020","journal-title":"Expert Opin Pharmacother"},{"key":"B316","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1001\/jama.2017.0332","article-title":"Screening for obesity and intervention for weight management in children and adolescents: evidence report and systematic review for the US preventive services task force","volume":"317","author":"O'Connor","year":"2017","journal-title":"JAMA"},{"key":"B317","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ejphar.2016.12.018","article-title":"A novel and selective melanin-concentrating hormone receptor 1 antagonist ameliorates obesity and hepatic steatosis in diet-induced obese rodent models","volume":"796","author":"Kawata","year":"2017","journal-title":"Eur J Pharmacol"},{"key":"B318","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1080\/14656566.2016.1244527","article-title":"An update on naltrexone\/bupropion extended-release in the treatment of obesity","volume":"17","author":"Saunders","year":"2016","journal-title":"Expert Opin Pharmacother"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2021.623681\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,11]],"date-time":"2021-03-11T23:21:46Z","timestamp":1615504906000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2021.623681\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,12]]},"references-count":318,"alternative-id":["10.3389\/fpsyt.2021.623681"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2021.623681","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,12]]},"article-number":"623681"}}